PrecivityAD2 is a blood test that helps diagnose Alzheimer's disease by measuring amyloid-related proteins in plasma. In 2026 it became the first Alzheimer's blood test cleared for symptomatic adults as young as 40, with strong accuracy against PET or spinal-fluid amyloid but only as part of a clinical workup. Younger-onset Alzheimer's begins before age 65, often in the 40s and 50s. For these patients the road to an answer can be long and uncertain, so the test fills a practical need in primary care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can use PrecivityAD2 now?
- How accurate is the test?
- What changes for primary-care patients?
- Where do limits and gaps remain for younger patients?
Who can use PrecivityAD2 now?
The test is for adults 40 and older who have cognitive symptoms and receive a clinical assessment. As described in the C2N Diagnostics announcement, C2N Diagnostics received FDA clearance on Aug. 20, 2026 for this symptomatic group.
It is not cleared for screening without symptoms or as a standalone diagnosis. FDA labeling calls for use alongside clinical workup by experienced clinicians. In practice, ask your clinic about these checks:.
- age 40 or older
- memory, thinking, or functional changes you or family noticed
- in-person evaluation with history, exam, and cognitive testing
- plan for follow-up testing if results and symptoms disagree
How accurate is the test?
In the 1,142-person FDA validation cohort with cognitive symptoms, a positive result had 97.6% positive predictive value and a negative result had 93.1% negative predictive value versus PET or spinal-fluid amyloid, according to Healio reporting on the company validation results. An independent validation cited by C2N reported 91% overall accuracy, with 90% sensitivity and 92% specificity versus amyloid PET at the standard cutoff. The test uses high-resolution mass spectrometry to measure plasma Aβ42/40 and p-tau217 ratios.
It reports an amyloid-pathology score that supports, but does not replace, clinical judgment. A positive score raises the likelihood of amyloid pathology. A negative score lowers it. Neither result alone names the cause of symptoms.
What changes for primary-care patients?
Primary-care accuracy is often modest without biomarker help. In a 1,310-patient Swedish study presented at AAIC 2026, accuracy rose from 65% to 93% after PrecivityAD2 results, near dementia specialists at 94%, as reported by AJMC in its coverage of the clearance and primary-care data. That shift matters for younger adults.
They often see several clinicians before Alzheimer's enters the differential. A blood result gives the primary-care doctor a concrete next step toward referral, further testing, or alternate causes. Bring a symptom timeline, medication list, sleep and mood history, and a family observer when possible. Clear examples of work impact, missed steps, or language trouble help the clinician interpret the score.
Where do limits and gaps remain for younger patients?
Younger patients face longer, harder workups because age points away from Alzheimer's and symptoms can be atypical, according to Alzheimer's Association guidance. A blood test does not remove that complexity. As of Oct.
2026, Diagnostics World News reported that no country had placed Alzheimer's blood tests into official primary-care protocols and fewer than one in four primary-care clinicians reported using them. Access, clinician experience, counseling, and follow-up paths still vary by clinic. If symptoms persist after a negative result, ask about recheck timing, other neurologic or medical causes, and specialist referral. If the result is positive, ask what confirmatory steps, care planning, support services, and treatment discussions come next.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Primary Care Patients Can Bring to a Clinician
